

Hitting the High Points of Medical Cannabis

Joseph Friedman RPh MBA Founding Member, Principal, & Chief Operations Officer **PDI** Medical #NCPA2017

(Professional Dispensaries of Illinois)

Disclosures

Joseph Friedman, RPh, MBA is Chief Operations Officer, PDI Medical. The conflict of interest was resolved by peer review of the slide content.

Bradley Carlson, PharmD is Principal Consultant, CannaRPH, LLC. The conflict of interest was resolved by peer review of the slide content.





Learning Objectives

- Describe the unique challenges and opportunities for pharmacists in the medical marijuana industry.
- Discuss the health benefits and possible side effects for patients using medical marijuana for health-related conditions.
- Evaluate the business dynamics and opportunities of the medical cannabis industry, and the growth curve of medical cannabis.





In Loving Memory







Hey, Wadda ya think about an Informal Survey?

Should we have Pharmacist involvement in our nations medical cannabis industry?

YES



NO





JOE & BRAD AT YOUR SERVICE!

- History of Marijuana Prohibition
- Federal Government
- State Government
- The Medical Cannabis Business Environment
- PDI Medical A Day In The Life
- Pharmacist Involvement
- Medical Cannabis Educational Opportunities
- Chicago Based Aclara Research
- CBD Opportunities for Drug Stores
- CannaRPh A New and Unique Consulting and Educational Organization

#NCPA2017

Joseph Friedman, R.Ph.

History, Politics, Legal, Business, Research, & Drug Store Opportunities

Bradley Carlson, Pharm D.

Cannabis Science, Pharmacology, Pharmacokinetics, & Dosing



Good Afternoon










FEDERAL GOVERNMENT Marijuana Prohibition 2017















Science Calls Out Jeff Sessions on Medical Marijuana and the "Historic Drug Epidemic"


Rolling back protections from federal interference in state legalization laws could worsen the opioid overdose crisis

- University of Michigan The Journal of Pain, July 2016 Survey: 64% drop in opioid use
- JAMA 2014 Annual Opioid deaths 25% lower on average
- Health Affairs, July 2016 Medicare Part D: Typical MD prescribed 1,826 fewer painkiller doses. Less antidepressants, anti-nausea and anti-anxiety drugs.



Dina Fine Maron Scientific American - June 14





MEDICAL CANNABIS STATES

• OHIO

NEW YORK

NORTH DAKOTA

• PENNSYLVANNIA

• RHODE ISLAND

• WEST VIRGINIA

VERMONT

- ARIZONA
- ARKANSAS
- CALIFORNIA
- CONNECTICUT
- DELAWARE
- FLORIDA
- HAWAII
- ILLINOIS
- LOUISIANA
- MARYLAND • MICHIGAN
- MINNESOTA
- MONTANA
- NEW HAMSHIRE
- NEW JERSEY
- NEW MEXICO

LEGAL CANNABIS STATES

- ALASKA
- COLORADO
- D.C.
- MAINE
- MASSACHUSETTS
- NEVADA
- OREGON
- WASHINGTON





Do Cannabis Dispensary Staff Receive Sufficient Training?

- Mean Age 31.9 years (22 63)
- Caucasian 86%
- Female 55%, Male 45%
- Full Time 84%
- Average Salary \$15/hr (\$8 \$25)
- Medical or scientific training 20%
- Giving advice to patients 94%
- Formal training 55%

"Some of the cannabis recommendations made by dispensary staff have not been shown to be effective and could even cause a patient's condition to worsen."



Training and Practices of Cannabis Dispensary Staff, 2016 - Nancy A. Haug, Dustin Kieschnick, James E. Scottile, Kimberly A. Babson, Ryan Vandrey, and Marcel O. Bonn-Miller



Pharmacists should play 'front-line' role in dispensing cannabis

- APHA: American Pharmacists Association
- Canadian Pharmacists Association
- Pharmacist Mandate
 - Connecticut
 - New York
 - Minnesota
 - Arkansas
 - Pennsylvania





Pharmacists and Medical Cannabis The Risks and Benefits of Cannabis Therapy

- Real drug with real side effects
- Pharmacists are the drug experts
 - Basic skills
 - Necessary training and education
 - Practical Experience
 - Patient-focused mindset
 - Pharmacists are healthcare professionals
 - The public trusts us





Pharmacists and Medical Cannabis The Risks and Benefits of Cannabis Therapy

- Gallop Poll Honesty/Ethics in Professions
 - Nurses 29%
 - Pharmacists 15%
 - Car Salesman 1%
 - Members of Congress 1%

Pharmacist Gallop Poll History

Nov 1999 – 18%

Nov 2004 - 19%

Nov 2007 – 16%

Nov 2012 – 19%

Dec 2016 - 15%

SO WHAT ARE THE ISSUES?





Pharmacists and Medical Cannabis The Risks and Benefits of Cannabis Therapy

- Pharmacists are the best positioned professional to head up this industry
- Historical Gallop Poll
 - Pharmacist damage Must rebuild Can possibly do it now with medical cannabis involvement
 - High cost of generics
 - Chicago Tribune, December 2016
 - Investigation of deadly drug interactions failure to warn patients
 - Clarithromycin and Ergotamine
 - · Simvastatin and Clarithromycin
 - · Colchicine and Verapamil
 - Tizanidine and Ciprofloxacin
 - · Norgestimate/ethinyl estradiol and Grisesofulvin





Pharmacists and Medical Cannabis The Risks and Benefits of Cannabis Therapy

Chicago Tribune Results - Failure Rates

The test was recorded as a fail if the store did not warn about the drug interaction and did not try to

discuss it with the prescribing physician

CVS	63%
Target	62%
Kmart	60%
All Chains Combined	49%
Wal-Mart	43%
Jewel-Osco	43%
Mariano's	37%
Walgreens	30%

Independent pharmacies 72%

NCPA NATIONAL COMMUNITY PHARMACISTS ASSOCIATION



Pharmacists and Medical Cannabis The Risks and Benefits of Cannabis Therapy

• State Medical Cannabis Programs with Pharmacist Mandate

Connecticut

New York

Minnesota

Pennsylvania


Arkansas

MORE COMING.....





















































PDI MEDICAL – A DAY AT THE DISPENSARY

- Patient Cases
- Patient Testimonials
- Pharmacy Students
- Standards of Care and Practice at PDI Medical





Patient Cases



Lisa K

Angela H

Daniel W





PDI Medical – A Day In The Dispensary

Lisa K

Celiac Disease

GERD

Sjogren's Syndrome

Polyarthralgias

Joint Hypermobility Myofascial Pain Syndrome

Neuritis/Neuropathy, Trigeminal Neuralgia from Arachnoid cyst

Raynauds Syndrome

Eczema

Asthma

Restless Leg Syndrome

Cognitive Impairment

Fibromyalgia

Myalgias, Myositis Ocular Migraines

Gastroparesis

IBS

Tendonitis both knees, Baker's cyst behind right knee









Coconut Oil 1.3:1.0 (1ml) RSO

- Harlequin Sativa Dominant Hybrid
- Bruce Banner Indica
- Canna Tsu Hybrid



THC 2.06%, CBD 3.4%





PDI Medical – A Day In The Dispensary

Angela HComplex Regional Pain Syndrome







Daniel W

Severe Fibromyalgia Spinal Stenosis RA 6 Herniated Discs

60 Epidurals 30 Trigger Point Injections 30 Nerve Ablations



23 Medications21 for pain & inflammation

Current drug therapy Lisinopril Levothyroxine Vitamin D


"Side effects of medical cannabis pale in comparison"

"Medical Cannabis changed my life"





PDI Medical – A Day In The Dispensary







An Incredible Patient Letter

August 28, 2017

Dear Cori,

I have a deep love for PDI Medical. Every time I walk in the door, I feel like I am coming home. I want to help spread the word about PDI's unique pharmacist-driven approach to medical cannabis patient care. I feel strongly about helping PDI fulfill its mission as an innovative leader in the dispensary business.

PDI Medical has changed my life. PDI gave me my first completely pain-free day after nearly a decade of chronic, intractable pain. I never thought relief was something that I could experience. I never thought that my quality of life would be better than 95% bedrest. The knowledgeable and caring professionals at PDI have taught me that life can get better, even from the darkest depths of pain and suffering.

I want everyone else to know what I know about PDI: how accessible and welcoming the staff are, how much compassion and knowledge exist inside your four walls, and how you are improving quality of life for your many patients above and beyond what a "normal" dispensary service offers.





PDI Medical – PHARMACY STUDENT CLINICAL ROTATIONS



















#NCPA2017



Sarah C., RN





PDI Medical Staff Holiday Party 2016



PDI Medical – A Day In The Dispensary



PDI CARES





DISPENSARY ACCREDITATION



NMMAO accreditation indicates a dispensary's achievement of a high level of organizational proficiency

- May Lower Insurance Premiums
- May reduce serious complaints
- Enhances reputation to peers, law enforcement, regulators, prescribers, community and patients
- Improves work culture, staff morale and relations

Jean Milford CEO, NMMAO 816-617-0658 Jean.Milford.MMConsulting@gmail.com

com NCPA



MEDICAL CANNABIS EDUCATION AND TRAINING HOLISTIC CANNABIS NETWORK (HCN) + HOLISTIC CANNABIS ACADEMY (HCA)

- * HCN is the only cannabis education program produced by holistic nutrition practitioners
- * HCN/HCA is the only cannabis education program that teaches how to integrate cannabis into "alternative" modalities
- * HCA provides patient education materials for immediate use with clients
- * HCA delivers tools + resources directly to your door
- * IHCA is a turnkey solution for busy professionals to integrate cannabis into their practices





MEDICAL CANNABIS EDUCATION AND TRAINING HOLISTIC CANNABIS NETWORK (HCN) + HOLISTIC CANNABIS ACADEMY (HCA)

Holistic Cannabis Practitioner

31 modules in 4 tracks

Exam leading to a certificate

Collateral materials to download

Hot off the presses resources delivered directly to you

Online access to 2016 Holistic Cannabis Summit

Private FaceBook page for networking

Google hangouts with HCA team



Credentialed professionals only



MEDICAL CANNABIS EDUCATION AND TRAINING HOLISTIC CANNABIS NETWORK (HCN) + HOLISTIC CANNABIS ACADEMY (HCA)

Curated Cannabis Packages

MMJ Primer (5 modules)

Herbal + Nutrition Toolbox (6 modules)


The Wellness Package (6 modules + bonus)


The Holistic Healer (4 modules)


Caregivers, patients, canna curious individuals















Cannabidiol or CBD - DEA vs. Mankind

Establishment of a New Drug Code for Marihuana Extract – Highlights

New drug code established for marijuana extracts – An extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other then the separated resin (whether crude or purified) obtained from the plant. Extracts of marihuana will continue to be treated as Schedule 1 controlled substances.

For practical purposes, all extracts that contain CBD will also contain at least small amounts of other cannabinoids.[1] However, if it were possible to produce from the cannabis plant an extract that contained only CBD and no other cannabinoids, such an extract would fall within the new drug code 7350. In view of this comment, the regulatory text accompanying new drug code 7350 has been modified slightly to make clear that it includes cannabis extracts that contain only one cannabinoid.

DEA FOOTNOTE







Cannabidiol or CBD – DEA vs. Mankind

DEA classification is a drug code, not a law

The senate makes laws, not the DEA.

Even if that were the law, the DEA recognized that Section 7606 protects hemp products out of approved industrial hemp research programs.


The DEA tacitly acknowledged that CBD sourced from industrial hemp cultivated lawfully pursuant to a State's industrial hemp laws enacted under the 2014 US Farm Bill is legal. This is because "industrial hemp" is itself specifically excluded from the CSA's definition of marijuana in Section 7606 of the Farm Bill.

Since industrial hemp is excluded from the definition of the CSA, and a "product consist[ing] solely of parts of the cannabis plant excluded from the CSA definition of marijuana" is not included in the new drug code, then such product (CBD) is also excluded from the definition of marijuana under the CSA and is thus legal, at least at the Federal level."

Although Federally legal, states have the ability to pass laws prohibiting CBD sales from Agricultural Programs. So far, Denver is the only governing body has done so.



Cannabidiol or CBD - DEA vs. Mankind







Cannabidiol or CBD - DEA vs. Mankind












UNDOO



THE CANNABIS SAFETY NET







THE CHOICE



VS




Rph-er Sanity



#NCPA2017





Carpe' Diem "seize the day" Latin aphorism from Book 1 of the Roman poet Horace's work Odes (23 BC)





Joseph Friedman RPh MBA

Founding Member, Principal, & Chief Operations Officer
PDI Medical
jfriedman@pdimedical.com
224-436-1634





Hitting the High Points of Medical Cannabis Part 2

Bradley Carlson, PharmD, RPh Pharmacist Consultant PDI Medical, LLC (Professional Dispensaries of Illinois) Co-Founder, Principal CannaRPh, LLC






Change in Paradigm: Cannabis <u>IS</u> Medicine




















#NCPA2017
www.ncpanet.org/convention

photo by B. Carlson, 2016






"What is half of 8?"

- Four (or 4)
- E or 3
- 0





Change in Paradigm: Cannabis IS Medicine







Session Objectives

At the end of this discussion, pharmacists will be familiar with:

- A Brief History of Cannabis as Medicine
- Overview of Endocannabinoid System, Cannabinoids, and targets for cannabis-based medications
- Summary of the role of synthetic cannabinoids, and compare to whole plant-based medication
- Compare and contrast common cannabis formulations and routes of administration, including pharmacokinetics and pharmacodynamics
- Clinical evidence for use of cannabis as medicine
- Use of cannabinoids for state-approved medical conditions.





QUICK POLL QUESTION!!!

How long has cannabis been utilized and valued by humans?

- 1. Approximately 400 years
- 2. Approximately 1000 years
- 3. Approximately 2000 years
- 4. Greater than 2000 years





BRIEF Cannabis History


- Plant has been valued for millennia!
- Used as medicine, textile, food
- Complex history of use and control of use
- Medical use and recreational use becoming more widely accepted in US (although being used medicinally in other countries for years)





photo by B. Carlson, 2016





Medical Cannabis vs. Recreational Marijuana

- How do we "RECOGNIZE" Cannabis as medicine???
- Recreational use titrates to a "high"
 - "Risk-Risk" utilization
- Medical use titrates to symptom relief
 - "Benefit Risk" utilization
 - PHARMACIST'S ROLE!!!!
- Some states allow different products / different quantities of product for medical vs. recreational
- PK / PD essentially the same; varies between patients and products





QUICK POLL QUESTION!!!


Chemicals found within Cannabis effect which areas of the body?

- 1. Brain and Central Nervous Syste
- 2. Gastrointestinal System
- 3. Musculoskeletal System
- 4. Immune System
- 5. Reproductive System









The Human Endocannabinoid System

- → Endocannabinoids and their receptors found throughout body: brain, organs, connective tissues, glands, and immune cells.
- In each tissue, the cannabinoid system performs different tasks; goal is always homeostasis
- When cannabinoid receptors are stimulated, a variety of physiologic processes occur
 - → CB1 receptors: nervous system, connective tissues, gonads, glands, organs
 - → CB2 receptors: immune system and associated structures
- Endocannabinoids are substances our bodies make naturally to stimulate CB1 and CB2
 - + Anandamide
 - → 2-arachidonoylglycerol (2-AG)

http://norml.org/library/item/introduction-to-the-endocannabinoid-system Accessed June 9, 2015 Neuro Endocrinol Lett. 2008 Apr;29(2):192-200.

Slide used from Borgelt with permission.





Endocannabinoid Pharmacology

- Anandamide
 - · partial agonist at CB receptors
 - slightly higher affinity for CB1
- · 2-arachidonyl glycerol
 - full agonist at CB1 receptor
- Stimulation of CB receptors has an effect to suppress neurotransmission at both excitatory and inhibitory synapses
- Ultimate action of CB stimulation is preservation of homeostasis varies greatly depending on organ/tissue
 - pain modulation, lipid metabolism, mood, motor function, appetite stimulation, GI function, CV function, etc.





Targets of Cannabis Therapies

CB1 Receptors

- + Basal ganglia
 - Motor activity
- + Cerebellum
 - Motor coordination
- + Hippocampus
 - → Short-term memory
- → Neocortex
 - Thinking
- → Hypothalamus & limbic
 - Appetite, sedation
- Pertaqueductal gray dorsol horn
 - + Pain
- + Immune cells

CB2 Receptors

- → Immunologic cells
 - → B lymphocytes
 - → Natural killer cells
- + Brain
 - + Role not established



Brit J Clin Pharm 2009;67:5-21. J Psychopharmacol 2008;22:707–16. J Psychopharmacol 2008;22:717–26. Slide used from Borgelt with permission.





Widespread CB Receptors

=

Many Potential Targets for Therapy



https://www.leafly.com/news/cannabis-101/cannabinoids-101-what-makes-cannabis-medicine Graphic by leafly.com. Used with permission.



Cannabis-Derived Pharmaceuticals

- → Single molecule pharmaceuticals
 - → Dronabinol (Schedule III)
 - → Nabilone (Schedule II)
- → Liquid extract: nabiximols (Sativex®)
 - + Approved in 27 countries; U.S. Phase III trials
- → Liquid extract: cannabidiol (Epidiolex®)
 - + FDA: orphan drug status for Dravet and Lennox-Gastaut syndromes
 - Expanded access INDs to several independent investigators
- ◆ Phytocannabinoid-dense botanicals
 - → Cannabis sativa medicinal plant
 - → (Schedule I)

Slide used from Borgelt with permission. Photo by Jon Lane, 2015. Used with permission.







Single Molecule Pharmaceuticals

- Dronabinol (Marinol®) synthetic THC
 - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics
 - anorexia associated with weight loss in patients with AIDS
- Nabilone (Cesamet®) synthetic THC similar
 - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics
- Both agents have been utilized off-label for other indications









Plant Extract Pharmaceuticals

Nabiximols (Sativex[®])

*Spasticity (muscle stiffness/spasm) due to Multiple Sclerosis

*Neuropathic pain in MS

***Adjunctive analgesic treatment in patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain

Cannabidiol (Epidiolex®)

- *Pediatric epilepsy
 - -Lennox-Gastaut Syndrome -Dravet Syndrome





8

Synthetics: A Thing of the Past?

• Whole Plant Extracts = Entourage Effect?





photo by Jon Lane, 2014. Used with permission.

Whole-Plant Extracts


- Cannabinoids
- Terpenes
- Lipids
- Flavonoids
- Sterols
- ENTOURAGE EFFECT!











QUICK POLL QUESTION!!!


Which of the following forms of Cannabis has the fastest onset of action?

- 1. Intravenous
- 2. Inhaled
- 3. Enteral
- 4. Sublingual









3 Most Common Routes of Administration



LUNGS Vaporized or Smoked

Organic material, hash, waxes & extracted oils



ENTERALOral Ingestion

Lipophilic, alcoholic, supercritical & subcritical oil extracts of plant material



TOPICAL Application

Creams, buccal tinctures, and patches made from plant extracts






All photos by B. Carlson, 2015, 2016.

Inhalation Delivery of Cannabis

- + Similar to IV bolus
- Passive diffusion into alveolar capillaries
- → Bioavailability: 2-56%
- → Fraction absorbed: 10-20%
- → Rapid onset (sec-min)
- Maximal onset 30 minutes and lasting 2-3 hours
- Metabolism in liver, lung, and brain
- + Elimination t½ = 20 hrs (2-13 days)
- Elimination primarily via feces (65%) and urine (20%)






Clin J Pain 2013;29:162-71. Brit J Clin Pharm 2009;67(1):5-21. Iran J Psychiatry. 2012;7(4):149–156. Clin Pharmacol Ther 2007;82:572-8. Pharmacol Rev 1986 Mar;38(1):21-43. Chem Biodivers. 2007;4(8):1770-804. Clin Pharmacol Ther 1980 Sep;28(3):409-16. Slide used from Borgelt with permission.



Enteral Delivery of Cannabis

- → Variable absorption
- → Bioavailability ranges 4-20%
- Onset: 30 minutes-2 hours
- → Duration: 5-8 hours
- → Metabolized primarily in the liver
 - + 11-hydroxy-THC
- → Elimination t½ = 20-30 hrs
- High inter- and intra-patient variability





Pharmacotherapy 2013;33:195-209 Brit J Clin Pharm 2009;67(1):5-21 Clin Pharmacol Ther 1980 Sep;28(3):409-16 Slide used from Borgelt with permission.



Cannabis Through the Oral Mucosa

- Onset: 15-40 minutes
- Duration: 45 minutes-3 hours
- → May have inter- and intra-patient variability
- → Plasma levels of THC and other cannabinoids are lower compared with the levels achieved following inhalation of cannabinoids at a similar dose (nabiximols)
- Metabolized in the liver
- → Elimination via feces (65%) and urine (35%)



Ther Adv Neurol Disorders. 2012;5(5):255-66. http://www.medicines.org.uk/emc/medicine/23262#PHARMACOKINETIC PROPS Slide used from Borgelt with permission.



Metabolism and Elimination

- Primary Hepatic via various CYP P450 Enzymes
 - THC = CYP2C9, CYP3A4
 - CBD = CYP2C19, CYP3A4
- Uridine diphosphate glucuronosyltransferases also play a role in metabolism
- *In vitro* Microsome studies suggesting many other elements involved in metabolism
- Other prescription medications influencing metabolism of Cannabis (and vice versa)



Slide modified from Birnbaum with permission.



Cannabis - Adverse Effects

- Serious Adverse Effects
 - psychosis
 - hypertension, increased pain, hyperemesis
 - birth defects
- Mild adverse effects
 - anxiety
 - disorientation, dizziness
 - · difficulty concentrating
 - headache
 - dry eyes
 - burning sensation in throat
 - numbness
 - Psychoactive effects (such as feeling "high")







ç

Cannabis - Safety Profile

- Therapeutic Index
- LD 50
- Deaths from use?





Drug - Drug Interactions



Back to issue

Drug Interactions with Marijuana

DECEMBER 09, 2014

John R. Horn, PharmD, FCCP, and Philip D. Hansten, PharmD

Marijuana has been approved for recreational use in 2 states and for medicinal use in about 20 states. Of course, the unapproved use of marijuana is fairly common. In addition to its recreational use, marijuana has been used (1) to control chemotherapy-induced nausea and vomiting and (2) as an analgesic, antispasmodic, appetite-stimulating agent, sedative, antiepileptic, and euphoric. Side effects associated with tetrahydrocannabinol (THC) include sedation, euphoria, dizziness, ataxia, tachycardia, hypotension, dry mouth, anxiety, and paranoia. THC is the primary psychoactive constituent of marijuana, but the plant contains more than 50 cannabinoids.

In addition to THC, cannabidiol (CBD) is found in high concentrations in marijuana. CBD does not produce any of the psychoactive responses and appears to block some of the effects of THC by acting as an antagonist at the cannabinoid receptors. Cannabinol is weakly psychoactive and appears to be primarily formed from the metabolism of THC. Another metabolite of THC is thought to contribute to the tachycardia and appetite-stimulating effects of cannabis.^{1,2}

The common natural sources of THC are *Cannabis sativa* and *Cannabis indica*. These differ in that *C sativa* is known to produce more of a "high" and lively feeling than *C indica*, which tends to produce a more relaxed feeling. This difference in response may be due to the THC:CBD ratios in the 2 plants. *C*



http://www.pharmacytimes.com/publications/issue/2014/december2014/drug-interactions-with-marijuana



Drug-Drug Interactions

- Opioids
- Benzodiazepines, "z-drugs"
- Anticoagulation
- Anti-epileptic drugs
- Antibiotics
- Anticholinergics
- Sympathomimetics







Key Point



Given the wide variety of formulations available, it is important to consider various pharmacokinetic and pharmacodynamic parameters.

A patient-determined, self-titrated dosing model should be used. The most effective and tolerable formulation and dose will vary based on body type, weight, and condition.

Providers need to step into a shared decision making model with patients.

Complex therapies NEED pharmacist Involvement!! #NCPA2017



Cannabis - Efficacy in Practice

- Few clinical trials exist
- Common phrase from practitioners:
 - "The jury is out" on efficacy
- Most evidence anecdotal
 - · from personal experience, very positive!
- Many clinical trials used products that are not whole plant extracts
- Dronabinol and Nabiximols commonly utilized in clinical evaluations





Clinical Trials: Medical Cannabis

SHOW ME THE MONEY!!!

A Review of Medical Cannabis Studies relating to Chemical Compositions and Dosages for Qualifying Medical Conditions

http://www.health.state.mn.us/topics/c annabis/practitioners/dosagesandcomp JULY 2017







Minnesota Statistics


Qualifying Condition	Patients Certified: N (%)
Glaucoma	53 (1%)
HIV/AIDS	63 (1%)
Tourette Syndrome	51 (1%)
ALS	18 (<1%)
Seizures	379 (6%)
Muscle Spasms	1055 (17%)
Inflammatory Bowel Disease, Including Crohn's Disease	238 (4%)
Cancer	742 (12%)
Terminal Illness	98 (2%)
Intractable Pain	4265 (69%)
Total	6184

*Patients certified total more than 100% because 11.9% of the 6184 patients have had more than one qualifying condition certified; in this table each certified condition is counted.




Information and graphic from MDH, used with permission.









Cannabis as Medicine??

• In my personal experience:

•IT WORKS!!!




Photo by Jon Lane, 2015. Used with permission.





Cannabis Research

- New dosage forms
 - Rectal, topical, transdermal, inhalation variations
- New indications
- Standardization of dosing
- Continued expansion of state programs
- Clinical trials?







Pharmacist Involvement

<u>IS ESSENTIAL</u>

for progression
of medical cannabis
and acceptance as
legitimate drug
therapy!!!





Conclusions

- Cannabis has been used and valued by humans for millennia
- Cannabis-derived medication works by regulating and supplementing the body's endocannabinoid system
- Synthetic cannabinoids have helped paved the way for medical use of cannabis; whole-plant extracts are the focus of many current medication producers
- Cannabis can be successfully utilized in a variety of different dosage forms, most commonly inhalation, oral and topical
- Cannabis is being used successfully by patients with many disease states with many symptoms; more research needs to be done to expand and standardize these practices
- Pharmacists will have a key role to play as dosage forms and indications expand






Special Thanks!!!

- Joseph Friedman
- Stuart Gimbel
- Dr. Laura Borgelt
- Dr. Angela Birnbaum
- Minnesota Department of Health
- Martin Lee
- Jon Lane







?QUESTIONS?





Contact information

www.cannarph.com

Joseph Friedman, RPh, MBA joseph.friedman@cannarph.com

Bradley Carlson, PharmD, RPh bradley.carlson@cannarph.com



